Abstract
Coronary artery disease, also known as ischemic heart disease , is the leading killer of men and women worldwide. In 2004, coronary artery disease was responsible for 7.2 million deaths, or 12.2% of all deaths globally and 5.8% of all years of life lost (World Health Organization 2008). The disease is highly prevalent: at any given time, 54 million people in the world suffer from angina pectoris (the characteristic chest pain of ischemic heart disease), and 23.2 million people experience moderate to severe disability as a result of ischemic heart disease 2008). Thirty-day mortality after an acute heart attack is extremely high at 33%; even in a hospital with a coronary care unit where advanced care options are available, mortality is still 7%. Approximately 4% of patients who survive initial hospitalization die in the first year following a heart attack (Antman et al. 2004). Congestive heart failure , the end stage of many heart diseases, carries a 1-year mortality rate as high as 40% and a 5-year mortality between 26 and 75%; the prognosis for patients with congestive heart failure is worse than for those with most malignancies or AIDS (McMurray and Stewart 2000). Pharmacologic therapy, metallic stents, and coronary artery bypass grafts have been mainstays of treatment for ischemic heart disease. However, new biomaterial devices are on the horizon that will enable optimal treatment of coronary artery lesions, as well as regeneration of damaged cardiac tissue.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Acharya G, Park K (2006) Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev 58:387
Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110:588
Aoki J, Serruys PW, van Beusekom H et al (2005) Endothelial progenitor cell capture by stents coated with antibody against CD34 : the HEALING-FIM (Healthy endothelial accelerated lining inhibits neointimal growth-first in man) Registry. J Am Coll Cardiol 45:1574
Ashley EA, Niebauer J (2004) Cardiology explained. Remedica, London
Ashrafian H, Dwivedi G, Senior R (2006) Assessing myocardial perfusion after myocardial infarction . PLoS Med 3:e131
Axel DI, Kunert W, Göggelmann C (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636
Christman KL, Lee RJ (2006) Biomaterials for the treatment of myocardial infarction . J Am Coll Cardiol 48:907
Christman KL, Vardanian AJ, Fang Q et al (2004) Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 44:654
Cutler DM, McClellan M (2001) Is technological change in medicine worth it? Health Affairs 20:11
Davis ME, Motion JP, Narmoneva DA et al (2005) Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 111:442
Eberhart RC, Su SH, Nguyen KT et al (2003) Bioresorbable polymeric stents: current status and future promise. J Biomater Sci Polym Ed 14:299
Fattori R, Piva T (2003) Drug eluting stents in vascular interventions. Lancet 361:247
Finn AV, Joner M, Nakazawa G et al (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization . Circulation 115:2435
Gaziano T, Reddy KS, Paccaud F (2006) Cardiovascular disease. In: Jamison DT, Breman JG, Measham AR et al (eds) Disease control priorities in developing countries, 2nd edn. IBRD/The World Bank and Oxford University Press, Washington, DC
Groeneveld PW, Matta MA, Greenhut AP et al (2008) Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 51:2017
Herrick JB (1912) Clinical features of sudden obstruction of the coronary arteries. JAMA 59:2015
Jawad H, Ali NN, Lyon AR et al (2007) Myocardial tissue engineering: a review. J Tissue Eng Regen Med 1:327
Jay V (2000) The legacy of William Heberden. Arch Pathol Lab Med 124:1750
Kawamoto A, Asahara T (2007) Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc Interv 70:477
Kellar RS, Shepherd BR, Larson DF et al (2005) Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng 11:1678
Kim W, Jeong MH, Kim KH et al (2006) The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab : ReoPro)-coated stent in acute myocardial infarction . J Am Coll Cardiol 47:933
Kipshidze N, Moussa I, Nikolaychik V et al (2002) Influence of Class I interferons on performance of vascular cells on stent material in vitro. Cardiovasc Radiat Med 3:82
Kohn J, Zeltinger J (2005) Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease . Expert Rev Med Devices 2:667
Lafont A, Li S, Garreau H et al (2006) PLA stereocopolymers as sources of bioresorbable stents: preliminary investigation in rabbit. J Biomed Mater Res B Appl Biomater 77:349
Lemos PA (2007) Polymeric stents: degradable but strong. Catheter Cardiovasc Interv 70:524
Li RK, Jia ZQ, Weisel RD et al (1999) Survival and function of bioengineered cardiac grafts. Circulation 100(suppl 19): II63
Maluenda G, Lemesle G, Waksman R (2009) A critical appraisal of the safety and efficacy of drug-eluting stents. Clin Pharmacol Ther 85:474
McGuigan AP, Bruzewicz DA, Glavan A et al (2009) Cell encapsulation in sub-mm sized gel modules using replica molding. PLoS One 3:e2258
McMurray JJ, Stewart S (2000) Heart failure: epidemiology, aetiology, and prognosis of heart failure . Heart 83:596
Mercado N, Boersma E, Wijns W et al (2001) Clinical and quantitative coronary angiographic predictors of coronary restenosis : a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 38:645
Miyahara Y, Nagoya N, Kataoka M et al (2006) Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction . Nat Med 12:459
Ormiston JA, Serruys PW, Regar E et al (2008) A bioabsorbable everolimus -eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899
Radisic M, Park H, Gerecht S et al (2007) Biomimetic approach to cardiac tissue engineering. Philos Trans R Soc Lond B Biol Sci 362:1357
Schatz RA, Baim DS, Leon M et al (1991) Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 83:148
Sharkawi T, Cornhill F, Lafont A et al (2007) Intravascular bioresorbable polymer stents: a potential alternative to current drug eluting metal stents. J Pharm Sci 96:2829
Shimizu T, Yamato M, Isoi Y et al (2002) Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimentional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res 90: e40
Stefanadis C, Toutouzas K, Stefanadi E et al (2007) Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab -eluting stent: an experimental study. Atherosclerosis 195:268
Tamai H, Igaki K, Kyo E et al (2000) Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 102:399
Tanimotos S, Serruys PW, Thuesen L et al (2007) Comparison of in vivo acute stent recoil between the bioabsorbable everolimus -eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 70:515
Virchow R (1856) Gesammalte abhandlungen zur wissenschaftlichen medtzin. Medinger Sohn & Co., Frankfurt
Weisz G, Leon MB, Holmes DR Jr (2006) Two-year outcomes after sirolimus -eluting stent implantation: results from the sirolimus-eluting stent in de Novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol 47:1350
White PD (1942) Book review: a short history of cardiology by Herrick JB. JAMA 202–203
World Health Organization (2008) The global burden of disease : 2004 update. WHO Press, Geneva
Zhang P, Zhang H, Wang H et al (2006) Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif Organs 30:86
Zimmer S, Jacobs B, Levy T et al (2002) Med Tech 101: the medical device handbook. Deutsche Bank Securities, Inc., New York, NY
Zimmermann WH, Melnychenko I, Wasmeier G et al (2006) Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 12:452
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Bhatia, S.K. (2010). Coronary Artery Disease. In: Biomaterials for Clinical Applications. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6920-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6920-0_2
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-6919-4
Online ISBN: 978-1-4419-6920-0
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)